Delving into the Latest Updates on LY-3053102 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Eli Lilly & Co.

Active Organization-

Inactive Organization

Eli Lilly & Co.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician.

Start Date01 Dec 2013

Sponsor / Collaborator

Eli Lilly & Co.

NCT01736241

/ CompletedPhase 1

A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3053102 in Healthy Subjects

The main purpose of this study was to evaluate the safety and tolerability of the study drug known as LY3053102 in healthy participants. The study also investigated how much of the study drug entered the blood stream and how long it took the body to dispose of the study drug. Information about any side effects that occurred was also collected. The study was expected to last approximately 8 weeks for each participant (up to 4 weeks from screening to the administration of study drug and an additional 4 weeks of follow up).

Start Date01 Dec 2012

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with LY-3053102

Login to view more data

100 Translational Medicine associated with LY-3053102

Login to view more data

100 Patents (Medical) associated with LY-3053102

Login to view more data

100 Deals associated with LY-3053102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	United States	Eli Lilly & Co.	01 Dec 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01736241 (CTgov)	Phase 1	-	41	Placebo	dqwlkrhjlk(ojcouuudjp) = limwbulboh glqykmmmvu (lbnavsahtm, ylkzzeinub - gspqkavocp) View more	-	19 Jul 2018
NCT02020616 (CTgov)	Phase 1/2	Diabetes Mellitus, Type 2	60	Placebo+Metformin	okaibethdk(cqmiuuyrli) = lbukfmuabc jvtiqhfxic (cyxaglocxj, hzhcnhiytt - gjbzymmmmy) View more	-	20 Dec 2017